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Quality control material for the detection of
somatic mutations in fixed clinical
specimens by next-generation sequencing
Catherine I. Dumur*, Jorge A. Almenara, Celeste N. Powers and Andrea Ferreira-Gonzalez
Abstract
Background: Targeted next generation sequencing (NGS) technology to assess the mutational status of multiple
genes on formalin-fixed, paraffin embedded (FFPE) tumors is rapidly being adopted in clinical settings, where
quality control (QC) practices are required. Establishing reliable FFPE QC materials for NGS can be challenging
and/or expensive. Here, we established a reliable and cost-effective FFPE QC material for routine utilization in
the Ion AmpliSeq™ Cancer Hotspot Panel v2 (CHP2) assay.
Methods: The performance characteristics of the CHP2 assay were determined by sequencing various cell line
mixtures and 55 different FFPE tumors on the Ion Torrent PGM platform. A FFPE QC material was prepared from
a mixture of cell lines derived from different cancers, comprising single nucleotide variants and small deletions
on actionable genes at different allelic frequencies.
Results: The CHP2 assay performed with high precision and sensitivity when custom variant calling pipeline
parameters where established. In addition, all expected somatic variants in the QC material were consistently
called at variant frequencies ranging from 9.1 % (CV = 11.1 %) to 37.9 % (CV = 2.8 %).
Conclusions: The availability of a reliable and cost-effective QC material is instrumental in assessing the
performance of this or any targeted NGS assay that detects somatic variants in fixed solid tumor specimens.
Background
The numerous cancer genome characterization efforts
that have emerged in the past years [1–3] have promoted
the development of targeted cancer therapeutics [4], in-
cluding single or combined inhibitory agents [5], which
reportedly are beneficial to individuals who have tumors
harboring specific somatic mutations in genes encoding
for proteins involved in cell growth, proliferation, and
survival signaling pathways [6–9]. Thus, molecular testing
to identify such mutations in clinical specimens to assess
patient eligibility for targeted therapies has become stand-
ard practice in the management of oncology patients.
The recent technological advances in next-generation
sequencing (NGS) and the applications in the field of
oncology are revolutionizing clinical testing for person-
alized treatment decisions for oncology patients [10]; as
well as the translational research field, where somatic
variant findings may enhance the development of novel
targeted cancer therapeutics, which could benefit individ-
uals with tumors harboring such mutations. A variety of
different NGS-based assays have been developed for
mutation identification that have the ability to detect all
mutation types, including single nucleotide variants
(SNVs), copy number variants (CNVs), insertion/deletions
(Indels) and translocations, in many samples and many
genomic regions simultaneously, while providing a digital
readout of mutation frequencies.
The advent of NGS benchtop sequencers has allowed
the rapid adoption of molecular testing for somatic mu-
tations in clinical settings [11–13]. Thus, amplifying
discrete or targeted regions of the genome has allowed
for the development of panels of “amplicon sequen-
cing.” As an example, the Ion AmpliSeq™ Cancer Hot-
spot Panel v2 (Life Technologies, Carlsbad, CA), which
targets 207 exonic regions across 50 cancer-relevant
genes, is producing robust results starting from 1 to
10 ng of DNA isolated from formalin-fixed, paraffin
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embedded (FFPE) specimens [14]. Such an assay can
yield up to 1 gigabyte (Gb) of DNA sequence in the Ion
Torrent Personal Genome Machine™ (PGM), depending
on the chip used to run the sequencing reaction, in
short DNA fragments. Similarly, the TruSeq Amplicon
- Cancer Panel (Illumina, Inc., San Diego, CA), assay
allows the sequencing of mutational hotspots located in
212 exonic regions corresponding to 48 cancer-related
genes on the Illumina MiSeq, from 250 ng of DNA
sample. These NGS platforms provide the benefit of
targeting multiple genomic regions in a single reaction,
thus lowering the cost of the assay and allowing for
testing multiple genes in small samples.
However, the performance characteristics of NGS-
based clinical assays needs to be assessed during the
assay validation process, and ensured during routine
clinical runs [15]. One of the remaining challenges for
NGS-based clinical assays is the availability of robust,
cost effective, reference or quality control (QC) material.
Access to such material is crucial to be able to generate
confident NGS results, while managing potential workflow
variability from sample extraction to sequencing, data ana-
lysis pipeline and variant calling.
In this study we describe the analytical and clinical
validation of a 50-gene NGS assay, the Ion AmpliSeq™
Cancer Hotspot Panel v2 (CHP2), performed on the Ion
Torrent PGM, for clinical testing, as well as the develop-
ment of a robust, and relatively low cost, QC material to
assess performance characteristics during routine clinical
runs.
Materials and methods
Cell lines
DNA isolated from fresh-frozen, as well as from formalin-
fixed, paraffin-embedded (FFPE) cell pellets from mel-
anoma (SK-MEL28), pancreatic (MIA-PaCa-2), colon
(HCT116), and lung (H1975) cancer cell lines was used.
All the cell lines were obtained from American Type
Culture Collection (ATCC-http://www.atcc.org, Manassas,
VA). Each individual cell line DNA sample was sequenced
alone or combined with others in different proportions,
resulting in various sample mixes harboring different mu-
tations, at different frequencies.
Tissue specimens
Fifty five de-identified archival DNA samples isolated
from FFPE tissue blocks containing greater than 40 % neo-
plastic cells (43 non-small cell lung carcinoma (NSCLC),
4 colorectal cancer, and 8 melanoma cases) with known
mutational status for the KRAS, EGFR and BRAF (in-
cluding 25 Negative and 30 Positive for mutations in at
least one of these three genes) were used for the clinical
validation of the CHP2 assay. These DNA samples had
previously been isolated from tumor-enriched samples by
manual Microdissection, when indicated by a pathologist.
Single gene mutation assays
KRAS mutations in codons 12 and 13 were detected by
Sanger sequencing, preceded by a Co-amplification at
Lower Denaturation-temperature PCR (COLD-PCR)
[16] step for allele enrichment, whereas EGFR mutations
in exons 18 to 21 were detected by Scorpion primer-
probes and Amplification Refractory Mutation Screening
(ARMS®) [17] technology using the real-time PCR-based
EGFR RGQ PCR assay (Qiagen, Valencia, CA) according
to the manufacturer’s recommendations. BRAF muta-
tions in the V600 codon, as well as specific SMAD4 and
RET variants, were detected by multiplex allele-specific
PCR (AS-PCR) reactions that co-amplify the variant
sequence and an upstream conserved sequence, where
amplicons were detected by capillary electrophoresis using
Lab-on-a-Chip technology. The primers used for the
multiplex AS-PCR amplification for BRAF, SMAD4 and
RET specific variants are listed in Table 1, along with the
resulting amplicon sizes.
DNA isolation
All tissue H&E stained slides were reviewed by a patholo-
gist who assessed percent tumor content and delineated
the tumor area for manual microdissection, if needed.
Ten-micron unstained FFPE slides were then manually
dissected, when indicated, and DNA was extracted using
the DNA mini kit as described by the manufacturer
(Qiagen, Germantown, MD). The same DNA extraction
method was used for the fresh-frozen and FFPE cell
line pellets and from specimens subjected to laser
capture microdissection (LCM). Double-stranded DNA
(dsDNA) yield and concentration was assessed by fluor-
ometry on the Qubit® 2.0 instrument (Life Technologies,
Carlsbad, CA)
Library preparation
The Ion AmpliSeq™ Cancer Hotspot Panel v2 (CHP2)
was used to generate 207 amplicons covering over
2,800 hotspots, indexed in the COSMIC database, in 50
cancer-related genes, from 1 to 10 ng of dsDNA for
each sample, using additional PCR cycles for the lowest
dsDNA concentrations. The multiplexed amplicons
were then used to generate barcoded libraries using the
Ion AmpliSeq™ Library Kit 2.0 and the Ion Xpress™
barcoded adapters (Life Technologies, Carlsbad, CA).
Amplified libraries were quantitated following the manu-
facturer's recommendations. Barcoded libraries were com-
bined to a final concentration of 7 pM, to achieve optimal
yield of clonal templated Ion Sphere™ Particles (ISPs), for
emulsion PCR (emPCR) and further ISP enrichment fol-
lowing the manufacturer's recommendations. Sequencing
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was performed on 316™ chips run on the Ion Torrent
PGM and analyzed with the Torrent Suite v4.0.2 Software.
The February 2009 assembly of the human genome (hg19,
GRCh37 Genome Reference Consortium Human Refer-
ence 37) was used as a reference.
Determining the Limit of Detection (LoD)
DNA mixes from the four fresh-frozen cell line pellets
used in this study were further diluted in DNA isolated
from a de-identified normal snap-frozen human pla-
centa to achieve several different variants at different
frequencies 39 variants in 24 genes. In addition, DNA
isolated from FFPE cell line pellets was combined in
different proportions to achieve 37 variants at different
frequencies in 23 genes.
Analytical performance evaluation
Robustness, repeatability and reproducibility were assessed
by preparing multiple libraries from the LoD sample mix-
tures and running them in different 316™ chips. Accuracy
was evaluated by comparing variant frequencies obtained
from individual cell lines with the results obtained by
the Genomics and Bioinformatics Group (GBG) from
NCI, by querying the CellMiner database [18]. In
addition, libraries from the 55 patient samples and from
the well-characterized reference DNA sample NA12878
from the HapMap project [19] were sequenced and
compared to single gene mutation assay results to fur-
ther assess the accuracy of the CHP2 assay.
Data analysis pipeline
The sequencing data generated by the Ion Torrent
PGM was stored and analyzed in the Linux-based Ser-
ver, based on Ubuntu operating system, connected to
the instrument. The file types created during sequen-
cing included: raw image acquisition . DAT files; base-
calling, resulting in an unmapped BAM format file; and
alignment to the reference genome using the TMAP
aligner algorithm, with the output being a BAM file. Out-
put BAM files, along with target regions BED files, were
used for variant identification by the VariantCaller plugin.
Visualization of the raw alignments was assessed using the
Broad's Integrative Genomics Viewer (IGV 2.3.11) [20].
Variant calling
The Torrent VariantCaller (TVC) plugin was used to
identify and evaluate variants. The CHP2 assay was vali-
dated with the TVC 4.0 version of the plugin. The TVC
4.0 is designed to call SNVs, multi-nucleotide variants
(MNVs), insertions (INS), and deletions (DEL). The ana-
lysis pipeline uses FreeBayes, based on user-modifiable
parameters, such as coverage, quality, strand bias, and ho-
mopolymer length, among others, to discover candidate
variant locations, which are subsequently scored using
adaptive signal model and filtered. FreeBayes [21] is a
haplotype-based variant detector that runs in a Bayesian
statistical framework, which is capable of modeling multi-
allelic loci in sets of individuals with non-uniform copy
number. Afterwards, a second module performs assembly
of reads to detect long INS and/or DEL (Indels). A set of
seven barcoded FFPE cell line mix samples with known
variant frequencies were used to establish cutoff values for
critical TVC parameters to achieve enough stringency
(fewer false positives), while maintaining high sensitivity
(fewer false negatives) in the variant calling process. For
each critical parameter, z-scores of normally distributed
data were calculated to establish cutoff values to be used
the custom TVC plugin parameters, which were recorded
in a JSON text format. We used the Shapiro-Wilk normal-
ity test [22] to assess the normality of the critical parame-
ters distribution.
Quality Control (QC) material
QC material was prepared by growing the four cell lines
in individual T-75 flasks up to right before they reach
confluence. Then, cells were scrapped off each flask and
pooled together in PBS. This cell mixture was centrifuged
for 10 min at 1800 rpm and the supernatant was decanted.
The cell pellet was then resuspended in 500 μL of normal
human plasma. Fifty μL of thrombin solution (Siemens
Healthcare Diagnostics Inc., Tarrytown, NY) were added
Table 1 ASPCR Primers
Amplicon Name Primer Sequence (5'-3') Amplicon
Size (bp)
BRAF_conserved BRAF-F1:
TGCTTGCTCTGATAGGA
241
BRAF_R:
CTAGTAACTCAGCAGCA
BRAF_V600E BRAF-F2:
TGGTCTAGCTACAGA
141
BRAF_R:
CTAGTAACTCAGCAGCA
SMAD4_conserved SMAD4_F1:
TTGTCTTTTCTTTAGGGC
286
SMAD4_R:
AAGATAGTTCTTTTCTTTTGG
SMAD4_48586344_C > T SMD4_F2:
ATTTAGTGGTGATTGAAAT
181
SMAD4_R:
AAGATAGTTCTTTTCTTTTGG
RET_conserved RET_F1:
GTGCTATTTTTCCTCACA
268
RET_R:
AGGGCTATAAAAAGCTTAG
RET_43615612_A > G RET_F2:
GCTTGTCCCGG
176
RET_R:
AGGGCTATAAAAAGCTTAG
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Table 2 Variants identified in DNA isolated from frozen cell line mixes
Cell Line /
Sample
Name
HCT116 MiaPaCa-2 H1975 SK-MEL-28 4-Cell Line Mix Human
Placenta
4-Cell Line Mix
(Dil 1:2)
4-Cell Line Mix
(Dil 1:3)
Gene Symbol hg19 Coordinates Variant Type Variant Freq. (%) Found Found Found Found Expected Found Found Expected Found Expected Found
ABL1 133738370 SNV G 52.4 N.A. N.A. N.A. 13.1 12.6 ± 0.5 N.A. 6.1 6.3 ± 0.2 4.1 4.4 ± 0.5
APC 112175770 SNV A 98.1 74.4 51.7 88.5 78.1 80.0 ± 0.9 2.1 40.7 40.8 ± 0.9 27.8 29.4 ± 0.8
ATM 108138003 SNV C N.A. N.A. N.A. N.A. N.A. N.A. 55.8 27.9 32.1 ± 0.2 37.2 40.6 ± 0.4
BRAF 140453136 SNV A N.A. N.A. N.A. 99.3 24.8 21.7 ± 4.0 N.A. 12.3 13.7 ± 0.2 8.2 9.6 ± 0.2
CDKN2A 21971153 SNV T N.A. N.A. 96.4 N.A. 24.1 35.7 ± 2.6 N.A. 16.9 10.4 ± 1.1 11.3 8.4 ± 0.9
CSF1R 149433596 SNV C 99.6 99.3 100.0 N.A. 74.7 58.6 ± 4.5 90.5 72.9 68.8 ± 0.6 78.8 80.5 ± 1.2
CSF1R 149433597 SNV T 99.6 99.1 100.0 N.A. 74.7 62.3 ± 9.8 93.2 74.3 76.9 ± 0.7 80.6 85.7 ± 0.8
CTNNB1 41266134 DEL CTT 50.2 N.A. N.A. N.A. 12.5 10.7 ± 1.8 N.A. 4.7 4.8 ± 0.6 3.2 3.1a ± 0.1
EGFR 55242487 SNV T N.A. N.A. N.A. 99.3 24.8 22.8 ± 2.6 N.A. 12.3 13.4 ± 0.1 8.2 8.0 ± 0.6
EGFR 55249063 SNV A 100.0 23.2 70.6 100.0 73.4 75.3 ± 1.7 97.6 85.9 84.4 ± 0.7 89.8 90.1 ± 0.3
EGFR 55249071 SNV T N.A. N.A. 70.7 N.A. 17.7 27.1 ± 2.5 N.A. 12.7 13.6 ± 1.1 8.4 8.9 ± 1.2
EGFR 55259515 SNV G N.A. N.A. 56.7 N.A. 14.2 17.8 ± 0.7 N.A. 9.2 8.8 ± 1.3 6.1 6.4 ± 0.5
ERBB4 212812097 SNV G 100.0 N.A. 75.9 N.A. 44.0 54.0 ± 0.2 62.9 58.4 46.8 ± 1.6 59.9 59.0 ± 2.3
FGFR3 1807894 SNV A 100.0 100.0 99.6 100.0 99.9 99.6 ± 0.2 100.0 99.9 99.9 ± 0.1 99.9 99.8 ± 0.1
FLT3 28602367 SNV A 46.9 N.A. N.A. N.A. 11.7 15.4 ± 3.2 N.A. 8.8 7.0 ± 0.3 5.9 6.4 ± 0.8
FLT3 28610183 SNV C 100.0 66.5 99.6 69.2 83.8 80.9 ± 1.1 100.0 90.9 90.8 ± 0.1 93.9 93.4 ± 0.5
HRAS 534242 SNV C 99.5 61.9 40.4 46.9 62.2 67.6 ± 1.1 2.6 34.7 32.0 ± 0.2 24.0 21.5 ± 1.2
KDR 55946354 SNV A 48.5 N.A. N.A. N.A. 12.1 15.9 ± 1.0 51.3 33.3 34.5 ± 1.1 39.3 41.0 ± 1.1
KDR 55972974 SNV T 52.6 N.A. N.A. N.A. 13.1 13.2 ± 4.3 N.A. 8.1 7.3 ± 0.5 5.4 5.1 ± 0.1
KRAS 25398281 SNV A 46.4 N.A. N.A. N.A. 11.6 11.3 ± 0.7 N.A. 5.9 6.2 ± 0.4 3.9 4.2 ± 0.1
KRAS 25398285 SNV T N.A. 99.9 N.A. N.A. 25.0 24.7 ± 1.2 N.A. 12.8 13.7 ± 0.5 8.5 9.5 ± 0.1
MET 116339672 SNV T N.A. 72.9 N.A. N.A. 18.2 15.3 ± 2.0 N.A. 6.9 7.9 ± 0.0 4.6 4.8 ± 0.1
NOTCH1 139390822 SNV G N.A. 100.0 N.A. N.A. 25.0 22.5 ± 0.3 N.A. 11.1 9.3 ± 0.2 7.4 7.1 ± 0.1
PDGFRA 55141055 SNV G 99.7 100.0 99.7 100.0 99.8 99.9 ± 0.2 99.9 99.8 99.9 ± 0.1 99.8 100.0 ± 0.1
PDGFRA 55152040 SNV T N.A. N.A. 50.8 N.A. 12.7 11.8 ± 2.8 3.8 8.8 7.5 ± 0.1 7.1 6.0 ± 0.7
PIK3CA 178917005 SNV G N.A. N.A. 100.0 N.A. 25.0 28.6 ± 7.6 N.A. 11.6 13.9 ± 0.1 7.8 10.2 ± 0.6
PIK3CA 178927410 SNV G N.A. N.A. 45.1 N.A. 11.3 10.7 ± 1.2 N.A. 5.8 5.9 ± 0.2 3.9 4.0 ± 0.2
PIK3CA 178952085 SNV G 47.7 N.A. N.A. N.A. 11.9 11.3 ± 2.3 N.A. 4.9 6.4 ± 0.4 3.2 3.9a ± 0.1
PTEN 89711881 SNV G N.A. N.A. N.A. 99.3 24.8 24.3 ± 1.0 N.A. 11.8 9.5 ± 0.8 7.9 8.4 ± 0.6
RET 43613843 SNV T 100.0 65.8 100.0 N.A. 66.4 70.8 ± 2.1 100.0 86.1 86.8 ± 0.6 90.7 91.3 ± 0.5
D
um
ur
et
al.D
iagnostic
Pathology
 (2015) 10:169 
Page
4
of
16
Table 2 Variants identified in DNA isolated from frozen cell line mixes (Continued)
RET 43615612 SNV G 45.2 N.A. N.A. N.A. 11.3 15.1 ± 0.3 N.A. 7.4 7.2 ± 0.3 5.0 2.9 ± 0.5
RET 43615633 SNV G N.A. 64.5 N.A. N.A. 16.1 14.1 ± 0.0 N.A. 7.1 7.6 ± 0.5 4.7 3.7 ± 1.1
SMAD4 48586344 SNV T 47.6 N.A. N.A. N.A. 11.9 17.2 ± 1.4 N.A. 8.1 6.5 ± 0.2 5.4 4.9 ± 0.2
SMARCB1 24176287 SNV A 50.7 N.A. 40.8 N.A. 22.9 22.0 ± 2.3 N.A. 11.8 14.6 ± 0.1 7.9 10.7 ± 0.4
SMO 128846374 SNV A 52.6 N.A. N.A. N.A. 13.1 10.5 ± 1.5 N.A. 5.8 7.8 ± 2.0 3.9 4.4 ± 0.2
TP53 7577025 SNV T N.A. N.A. N.A. N.A. N.A. N.A. 79.0 39.5 29.1 ± 1.5 52.6 41.4 ± 1.1
TP53 7577120 SNV A N.A. N.A. 99.9 N.A. 25.0 31.6 ± 2.6 N.A. 16.7 20.8 ± 0.8 11.1 16.0 ± 0.1
TP53 7577539 SNV T N.A. 99.5 N.A. N.A. 24.9 18.8 ± 0.7 N.A. 9.6 11.3 ± 0.1 6.4 9.1 ± 0.1
TP53 7579472 SNV G 94.2 N.A. 94.2 N.A. 47.1 63.6 ± 8.9 20.4 45.1 54.3 ± 2.3 36.9 42.7 ± 1.7
Freq. Frequency; N.A., Not Applicable; a, these variants were called 90 % of the time
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to the cell pellet/plasma mixture to allow a clot to form.
The cell-containing clot was further fixed in formalin for
9 h (typical fixation time for human tissues in our labora-
tory), and embedded in paraffin following the routine
processing for fine-needle aspiration (FNA) cell pellets.
DNA was isolated from a single 10-μm section from
the cell mixture block, in parallel with patient samples
in each batch of samples, and was sequenced in every
run as an individual barcoded library with six more
libraries from patient samples in 316™ chips. For the
QC material, variants and their frequencies were first
assessed by sequencing this material in 10 consecutive
runs on the Ion Torrent PGM to establish the perform-
ance characteristics (i.e., Mean, +2SD, +3SD, etc.…) of
each variant. After implementing this quality control
material in clinical runs, the same variants and their
frequencies were monitored over time using Levey-
Jennings control charts.
Results
Analytical performance characteristics
From the DNA dilution experiments, where DNA iso-
lated from the four fresh-frozen cell line pellets was
further diluted in DNA isolated from a de-identified
Fig. 1 Limit of Detection (LoD) and linearity of the CHP2 assay. DNA isolated from four fresh-frozen cell line pellets was further diluted in DNA isolated
from a de-identified normal human placenta. Variants were identified at the expected frequencies, down to 3 % mutant DNA in the context of normal
DNA for fresh-frozen samples, when barcoding up to 7 samples. Pearson correlation is shown. Dotted line denotes the equality line
Fig. 2 Precision of the CHP2 assay. A representative sample run using different barcodes on the same chip to assess repeatability (a), or the same
barcode on different chips to assess reproducibility (b). Pearson correlation is shown. Dotted line denotes the equality line
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Table 3 Variants identified in DNA isolated from FFPE cell line mixes
Cell Line/Sample Name HCT116 MiaPaCa-2 H1975 SK-MEL-28 4-Cell Line Mix H1975 Dil in MiaPaCa-2 (1:14)
Gene Symbol hg19 Coordinates Variant Type Variant Frequency (%) Found Found Found Found Expected Found Expected Found
ABL1 133738370 SNV G 37.0 N.A. N.A. N.A. 9.3 12.4 ± 2.6 0.0 N.A.
APC 112175770 SNV A 98.0 72.7 36.5 91.3 74.6 78.4 ± 1.2 70.2 65.4 ± 1.4
BRAF 140453136 SNV A N.A. N.A. N.A. 100.0 25.0 21.1 ± 2.5 0.0 N.A.
CDKN2A 21971153 SNV T N.A. N.A. 98.8 N.A. 24.7 17.9 ± 0.6 100.0a 98.6 ± 0.9
CSF1R 149433596 SNV C 100.0 100.0 100.0 N.A. 75.0 61.4 ± 2.6 100.0 99.9 ± 0.2
CSF1R 149433597 SNV T 95.7 96.1 97.2 N.A. 72.3 58.0 ± 3.7 96.2 97.2 ± 0.9
CTNNB1 41266134 DEL CTT 44.9 N.A. N.A. N.A. 11.2 12.9 ± 1.6 0.0 N.A.
EGFR 55242487 SNV T N.A. N.A. N.A. 100.0 25.0 20.9 ± 0.1 0.0 N.A.
EGFR 55249063 SNV A 100.0 35.6 75.3 100.0 77.7 74.0 ± 3.2 38.4 48.1 ± 0.6
EGFR 55249071 SNV T N.A. N.A. 74.8 N.A. 18.7 17.9 ± 0.9 5.2 30.4 ± 1.3
EGFR 55259515 SNV G N.A. N.A. 71.7 N.A. 17.9 13.1 ± 2.3 5.0 21.8 ± 0.8
ERBB4 212812097 SNV G 100.0 N.A. 72.3 N.A. 43.1 45.2 ± 3.7 5.1 26.8 ± 1.1
FGFR3 1807894 SNV A 100.0 100.0 100.0 100.0 100.0 100.0 ± 0.0 100.0 100.0 ± 0.0
FLT3 28602367 SNV A 49.5 N.A. N.A. N.A. 12.4 17.8 ± 0.8 0.0 N.A.
FLT3 28610183 SNV C 100.0 64.3 100.0 65.2 82.4 81.1 ± 0.8 66.8 69.0 ± 0.9
HRAS 534242 SNV C 98.9 47.8 38.9 48.5 58.5 60.6 ± 2.5 47.2 48.2 ± 2.9
KDR 55946354 SNV A 47.9 N.A. N.A. N.A. 12.0 17.9 ± 1.2 0.0 N.A.
KDR 55972974 SNV T 47.1 N.A. N.A. N.A. 11.8 16.8 ± 1.1 0.0 N.A.
KRAS 25398281 SNV A 47.7 N.A. N.A. N.A. 11.9 12.1 ± 1.8 0.0 N.A.
KRAS 25398285 SNV T N.A. 100.0 N.A. N.A. 25.0 36.6 ± 1.2 93.0 80.3 ± 1.4
MET 116339672 SNV T N.A. 70.3 N.A. N.A. 17.6 19.2 ± 0.8 65.4 43.2 ± 1.1
NOTCH1 139390822 SNV G N.A. 100.0 N.A. N.A. 25.0 33.4 ± 1.1 93.0 70.6 ± 1.5
PDGFRA 55141055 SNV G 100.0 100.0 100.0 100.0 100.0 100.0 ± 0.0 100.0 100.0 ± 0.0
PDGFRA 55152040 SNV T N.A. N.A. 51.3 N.A. 12.8 8.7 ± 0.2 3.6 18.1 ± 1.4
PIK3CA 178917005 SNV G N.A. N.A. 100.0 N.A. 25.0 14.7 ± 0.9 7.0 28.0 ± 0.8
PIK3CA 178927410 SNV G N.A. N.A. 47.1 N.A. 11.8 8.8 ± 0.0 3.3 13.5 ± 1.0
PIK3CA 178952085 SNV G 47.7 N.A. N.A. N.A. 11.9 12.3 ± 1.0 0.0 N.A.
PTEN 89711881 SNV G N.A. N.A. N.A. 100.0 25.0 18.8 ± 1.9 0.0 N.A.
RET 43613843 SNV T 100.0 67.5 100.0 N.A. 66.9 70.6 ± 2.8 69.8 76.2 ± 1.5
RET 43615612 SNV G 49.1 N.A. N.A. N.A. 12.3 14.6 ± 2.4 0.0 N.A.
RET 43615633 SNV G N.A. 65.1 N.A. N.A. 16.3 22.8 ± 0.1 60.5 44.9 ± 1.5
SMAD4 48586344 SNV T 50.6 N.A. N.A. N.A. 12.7 15.9 ± 1.6 0.0 N.A.
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Table 3 Variants identified in DNA isolated from FFPE cell line mixes (Continued)
SMARCB1 24176287 SNV A 52.1 N.A. 46.3 N.A. 24.6 20.2 ± 0.6 3.2 15.6 ± 1.0
SMO 128846374 SNV A 51.0 N.A. N.A. N.A. 12.8 12.7 ± 1.8 0.0 N.A.
TP53 7577120 SNV A N.A. N.A. 100.0 N.A. 25.0 20.7 ± 0.8 7.0 32.8 ± 1.6
TP53 7577539 SNV T N.A. 99.9 N.A. N.A. 25.0 27.6 ± 1.1 92.9 67.8 ± 1.4
TP53 7579472 SNV G 84.2 N.A. 90.8 N.A. 43.8 57.6 ± 8.3 6.4 37.9 ± 5.2
N.A., Not Applicable; a, the MiaPaCa-2 cell line has a homozygous deletion of the CDKN2A gene
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normal human placenta, we were able to detect the var-
iants, both SNV and DEL, at the frequencies listed in
Table 2. Since variants with frequencies near 3 % were
called only 90 % of the time, we established the limit of
detection (LoD) at 4 % mutant DNA in the context of
normal DNA for fresh-frozen samples, which were
detected 100 % of the time when barcoding up to seven
samples with an average coverage of near 2000X per
sample (Fig. 1). In addition, the same samples run using
different barcodes within the same chip, or the same
barcode on different chips, showed excellent correla-
tions indicating high repeatability and reproducibility,
respectively (Fig. 2).
From the DNA dilution experiments, where DNA iso-
lated from different FFPE cell line pellets was mixed in
different proportions, we were able to detect the vari-
ants, at different frequencies (Table 3) without affecting
the LoD found with DNA isolated from fresh-frozen
specimens, when barcoding up to seven samples with
an average coverage of near 1300X per sample.
In terms of accuracy, we correlated the variant find-
ings for the HCT116 and SK-MEL-28 cell lines analyzed
in this study with the results obtained by the Genomics
and Bioinformatics Group (GBG) from NCI, by query-
ing the CellMiner database [18]. This database contains
genomic information on the cell lines from the NCI-60
project. These cell lines have been intensely investigated,
and a comprehensive analysis of coding variants in these
cell lines have been identified by whole exome sequencing
(WES). Thus, we found that all but two variants had previ-
ously been identified by WES. In the HCT116 cell line,
two variants were not found on the CellMiner database:
SMAD4_48586344_C > T and RET_43615612_A >G.
The variant in the SMAD4 gene is located in an in-
tronic region; therefore it may not have been detected
by WES. In order to validate the presence of this
variant in our cell line, we designed a multiplex allele-
specific PCR (ASPCR) assay to assess the presence of
such variant, which, according to our results, seemed to
be found in our clone of HCT116 cells, in a heterozy-
gous fashion. Primers were designed to co-amplify a
conserved region of the SMAD4 gene (286 bp), encom-
passing the C > T variant, and a variant-specific ampli-
con (181 bp) in the same reaction tube. Two PCR
master-mixes were designed: one that would detect the
variant, and another one that would detect the normal
sequence in that position. Similarly, primers were de-
signed to co-amplify a conserved region of the RET
gene (268 bp), encompassing the A > G variant, and a
variant-specific amplicon (176 bp) in the same reaction
tube. As shown on Fig. 3, HCT116, but not the other
cell lines, showed evidence of the variant, confirming
our sequencing results.
In addition, we found 100 % agreement with the variants
identified by our CHP2 assay in the well-characterized ref-
erence DNA sample NA12878 from the HapMap project
Fig. 3 Multiplex ASPCR results. Novel variants found in the SMAD4 and RET genes were confirmed by ASPCR and capillary electrophoresis using
Lab-on-a-Chip technology performed on the 4 cell lines used in this study. For the SMAD4 gene, the 286 bp peak corresponds to a conserved re-
gion encompassing the C > T variant at the 48,586,344 position in the hg19 reference genome and the 181 bp peak corresponds to the variant-
specific amplicon. For the RET gene, the 268 bp peak corresponds to a conserved region encompassing the A > G variant at the 43,615,612 pos-
ition in the hg19 reference genome, and the 176 bp peak corresponds to the variant-specific amplicon
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[19] with those reported by others sequencing the same
genomic regions (Life Technologies, Carlsbad, CA).
Effect of formalin fixation and Laser Capture
Microdissection (LCM)
In order to assess the potential effects of formalin fix-
ation on variant identification, we sequenced DNA iso-
lated from fresh-frozen cell lines and from DNA
isolated from FFPE cell pellets prepared from the same
cell lines. We then compared the variants identified in
the fresh-frozen cell lines and their FFPE counterparts.
Excellent Pearson’s correlations were observed for all the
variant frequencies identified in each pair of samples (i.e.
MIA-PaCa-2 r = 0.989, HCT116 r = 0.986, SK-MEL-28 r =
0.995, H1975 r = 0.992; p < 0.001).
In addition, we assessed the potential effects of Laser
Capture Microdissection (LCM) on variant detection by
sequencing DNA isolated from a whole tissue section
from a NSCLC case, containing near 70 % neoplastic cells,
and from DNA isolated from tumor cells enriched by
LCM from the same case. We then compared the variants
and their frequencies identified in each sample type. An
excellent Pearson’s correlation (r = 0.909, p = 7.3 x 10−8)
was observed between the two sample types, while
Pathogenic/Likely Pathogenic somatic variants, such as
EGFR NM_005228.3: c.2307_2308insGCCAGCGTG
(p.Val769_Asp770insAlaSerVal) and TP53 NM_000546.5:
c.659A >G (p.Tyr220Cys) were over-represented (i.e. at
higher allelic variant frequencies) in the LCM sample
compared to the whole tissue sample, as expected.
VariantCaller plugin parameters
The seven barcoded FFPE cell line mix samples with
known variant frequencies were used to establish cutoff
values for critical run and TVC parameters to achieve
enough stringency (fewer false positives), while main-
taining high sensitivity (fewer false negatives) in the
Table 4 Cutoff values for Ion Torrent PGM sequencing and TVC
parameters
Mean S.D. Confidence
Level
z Cutoff
(at z-score)
Coverage 1231 526 95 % 199 200
Number of
≥Q20 bases
2.5E + 07 2.4E + 06 95 % 2.0E + 07 2.0E + 07
Quality
(log10)
3.65 0.45 99 % 2.48 300a
Strand Bias 0.7 0.04 99 % 0.79 0.79
S.D., standard deviation; a, anti-logarithm of the found z value
Fig. 4 Normal quantile plots. The Shapiro-Wilk test was performed to assess the normality of the distribution of each of the adjustable parameters:
coverage (a), ≥Q20 Bases (b), TVC Quality (c), and TVC Quality (Log10) (d). The expected quantile line for a normal distribution is shown in red
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Table 5 Clinical specimen results for known KRAS, EGFR and BRAF mutations
KRAS or EGFR or BRAF Mutation Status
Sample_ID Single-Gene Assay CHP2 Assay
DNA_01 EGFR c.2369C > T (p.Thr790Met) EGFR c.2369C > T (p.Thr790Met)
DNA_02 EGFR c.2156G > C p.Gly719Ala EGFR c.2156G > C p.Gly719Ala
DNA_03 Negative Negative
DNA_04 Negative Negative
DNA_05 EGFR Exon 20 INS EGFR c.2307_2308ins9 (p.V769_D770insASV)
DNA_06 Negative Negative
DNA_07 Negative Negative
DNA_08 EGFR c.2369C > T (p.Thr790Met) EGFR c.2369C > T (p.Thr790Met)
DNA_09 EGFR c.2369C > T (p.Thr790Met) EGFR c.2369C > T (p.Thr790Met)
DNA_10 EGFR Exon 19 DEL EGFR c.2236_2250del15 (p.E746_A750delELREA)
DNA_11 Negative Negative
DNA_12 Negative Negative
DNA_13 Negative Negative
DNA_14 Negative Negative
DNA_15 Negative Negative
DNA_16 Negative Negative
DNA_17 Negative Negative
DNA_18 Negative Negative
DNA_19 Negative Negative
DNA_20 Negative Negative
DNA_21 KRAS c.35G > T (p.Gly12Val) KRAS c.35G > T (p.Gly12Val)
DNA_22 Negative Negative
DNA_23 EGFR c.2582 T > A (p.Leu861Gln) EGFR c.2582 T > A (p.Leu861Gln)
DNA_24 EGFR c.2582 T > A (p.Leu861Gln) EGFR c.2582 T > A (p.Leu861Gln)
DNA_25 Negative Negative
DNA_26 BRAF c.1799 T > A (p.Val600Glu) BRAF c.1799 T > A (p.Val600Glu)
DNA_27 KRAS c.34G > A (p.Gly12Ser) c.34G > A (p.Gly12Ser)
DNA_28 Negative Negative
DNA_29 EGFR c.2155G > A (p.Gly719Ser) EGFR c.2155G > A (p.Gly719Ser)
DNA_30 Negative Negative
DNA_31 Negative Negative
DNA_32 KRAS c.34G > T (p.Gly12Cys) c.34G > T (p.Gly12Cys)
DNA_33 BRAF c.1798_1799delGTinsAA (p.Val600Lys) BRAF c.1798_1799delGTinsAA (p.Val600Lys)
DNA_34 BRAF c.1798_1799delGTinsAA (p.Val600Lys) BRAF c.1798_1799delGTinsAA (p.Val600Lys)
DNA_35 EGFR Exon 19 DEL EGFR c.2235_2246del12 (p.Glu746_Glu749del)
DNA_36 Negative Negative
DNA_37 EGFR c.2573 T > G (p.Leu858Arg) EGFR c.2573 T > G (p.Leu858Arg)
DNA_38 EGFR c.2573 T > G (p.Leu858Arg) EGFR c.2573 T > G (p.Leu858Arg)
DNA_39 KRAS c.34G > T (p.Gly12Cys) c.34G > T (p.Gly12Cys)
DNA_40 Negative Negative
DNA_41 KRAS c.38G > A (p.Gly13Asp) c.38G > A (p.Gly13Asp)
DNA_42 KRAS c.38G > A (p.Gly13Asp) c.38G > A (p.Gly13Asp)
DNA_43 EGFR c.2573 T > G (p.Leu858Arg) Negative
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variant calling process. Critical parameters, including
those chosen to customize the TVC plugin, with their z
and cutoff values, are listed in Table 4. Graphical repre-
sentations of the Shapiro-Wilk normality test for three
of the critical parameters are shown in Fig. 4. Thus,
based on the normal distribution of the critical parame-
ters, the established cutoff values were used as custom
TVC plugin parameters, which were recorded in a JSON
text format. The TVC Quality parameter failed to show
a normal distribution, but the log10-transformed Quality
values did. Thus, a log10-transformed cutoff value was
calculated, instead.
Clinical specimens
After processing the previously tested 55 clinical speci-
mens, we compared the KRAS, BRAF and EGFR vari-
ants obtained by NGS with our previous single gene
assay results (Table 5). One clinical sample showed a
L858R mutation in the EGFR gene using the single gene
assay, which has a LoD of 1 % of mutant allelic fre-
quency, in the context of normal DNA, but that variant
was undetectable in the CHP2 assay. Upon visualizing
the BAM file with the IGV tool, we found that the vari-
ant was present in < 4 % of the reads (Fig. 5), therefore
below the LoD of the NGS-based assay. Thus, we found
that the CHP2 assay performs with 96.7 % sensitivity
and 100.0 % specificity for these three genes, when
compared to single gene assays, which have a LoD of
1 % for BRAF and EGFR, and 5 % for KRAS.
Common variants and artifacts
From the variants found in the 55 archived clinical sam-
ples, the four cell lines and the reference DNA sample
NA12878, we observed a number of recurrent variants
that seem to be detected in the majority of the samples. A
list of these common variants is shown in Table 6. Some
of the variants correspond to sequencing artifacts, such as
homopolymers [13]. Other variants seem to systematically
occur at the end of an amplicon, and others seem to cor-
respond to SNPs with a high global minor allele frequency
(MAF) (e.g., rs1050171 [A/G], MAF A: 0.4183).
Performance of the Quality Control (QC) Material
We have developed and implemented a high quality and
cost-effective control material for routine utilization in
the CHP2 assay on FFPE samples. This QC material
consists of a FFPE mixture of cell lines derived from
pancreatic (MIA-PaCa-2), colon (HCT116), melanoma
(SK-MEL28) and lung (H1975) cancer. This cell line
mixture was created to assess 8 somatic variants, includ-
ing 7 SNVs and 1 small DEL located in five different
genes (BRAF, EGFR, KRAS, PIK3CA, and CTNNB1) at
different allelic frequencies, and was subjected to formalin
fixation and paraffin embedding to mimic routine FFPE
clinical specimens. The performance characteristics of the
QC material were established over 10 consecutive runs.
Average reads on target for the QC material was 95.13 %
± 2.33 % and average uniformity on target areas was
98.26 % ± 0.68 %. During the initial 10 consecutive runs,
all expected somatic variants in the QC material were
consistently called at variant frequencies ranging from
9.1 % (CV = 11.1 %) to 37.9 % (CV = 2.8 %) (Table 7). Sub-
sequently, for every batch/run, DNA isolated from a single
10-μm section of this cell mixture block was barcoded
along with other six samples, and the allele frequencies for
variants called on the five genes were recorded and plotted
in Levey-Jennings charts for every clinical run (Fig. 6).
Discussion
In the recent years, NGS has been mainly used in genomic-
based research projects. The advent of cost-effective
desktop instruments, such as the Illumina MiSeq and
the Ion Torrent PGM, enabled the transition of NGS
from genomic research into the clinical arena. In order
Table 5 Clinical specimen results for known KRAS, EGFR and BRAF mutations (Continued)
DNA_44 EGFR Exon 20 INS c.2312_2314dupACC (p.Pro772delinsHisPro)
DNA_45 Negative Negative
DNA_46 Negative Negative
DNA_47 KRAS c.35G > T (p.Gly12Val) c.35G > T (p.Gly12Val)
DNA_48 Negative Negative
DNA_49 Negative Negative
DNA_50 BRAF c.1799 T > A (p.V600Glu) c.1799 T > A (p.V600Glu)
DNA_51 KRAS c.35G > A (p.Gly12Asp) c.35G > A (p.Gly12Asp)
DNA_52 BRAF c.1799 T > A (p.Val600Glu) BRAF c.1799 T > A (p.Val600Glu)
DNA_53 KRAS c.35G > T (p.Gly12Val) KRAS c.35G > T (p.Gly12Val)
DNA_54 EGFR c.2573 T > G (p.Leu858Arg) EGFR c.2573 T > G (p.Leu858Arg)
DNA_55 BRAF c.1799 T > A (p.Val600Glu) BRAF c.1799 T > A (p.Val600Glu)
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for NGS technology to translate into clinical testing, it
must meet the rigorous quality assurance and quality con-
trol protocols used in CLIA-certified laboratories and be
used on a routine basis, replacing single-gene assays. This
transition has already started, primarily for rare inherited
disorders, including prenatal testing, and cancer
theragnosis.
In this study, we assessed the performance characteris-
tics of the Ion AmpliSeq™ Cancer Hotspot Panel v2
(CHP2) assay by sequencing well-characterized cell lines
derived from pancreatic, colorectal, lung cancer, and
melanoma, as well as different mixtures of fresh-frozen
and FFPE DNA isolated from these cell lines. Thus, we
assessed the sensitivity of the CHP2 assay in detecting
low frequency somatic variants, or the assay’s limit of
detection (LoD), as well as the assay’s precision and
Fig. 5 Visualization of the L858R EGFR mutation. The EGFR T > G variant indicated by the black arrow at the 55,259,515 position in the hg19 reference
genome was present in a small number of reads and, therefore, was not called by the TVC
Table 6 List of common variants
Gene_Position_Variant Class
EGFR_55249063_G > A High Allele Frequency SNP
FGFR3_1807894_G > A High Allele Frequency SNP
FLT3_28610183_T > C High Allele Frequency SNP
PDGFRA_55141055_A > G High Allele Frequency SNP
CSF1R_149433596_A > C End of Amplicon
CSF1R_149433597_C > T End of Amplicon
STK11_1220321_T > C Homopolymer
PTEN_89711834_INS > T Homopolymer
RB1_48953805_DEL > A Homopolymer
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accuracy. In addition we evaluated the effects of sample
barcoding, formalin fixation and paraffin embedding, as
well as the impact of performing laser capture microdis-
section, on variant calling for these samples.
By establishing sequencing run quality control and
variantCaller (TVC) cutoff parameters, we were able to
customize the analysis pipeline for the CHP2 assay.
Thus, we assessed the accuracy of the assay by sequen-
cing 55 archival DNA samples, previously tested on
single-gene mutational analysis assays, as well as one
DNA sample from the HapMap project [19].
Overall, our results show that the CHP2 assay has a
LoD of 4 % of allelic frequency when barcoding up to 7
fresh-frozen and FFPE-derived DNA samples in a single
Ion 316™ chip, with good precision as shown by excel-
lent repeatability (intra-run) and reproducibility (inter-
run) metrics. Likewise, the CHP2 assay showed high
accuracy when correlating the variants found on DNA
isolated from the HCT116 and SK-MEL-28 cell lines,
which have been previously analyzed by WES by the
Genomics and Bioinformatics Group (GBG) from NCI
[18]. Thus, we found that 19 out of the 21 variants had
previously been identified by the NCI’s GBG. The two
unconfirmed variants seen in our laboratory were further
identified by ASPCR assays, confirming that these two
variants might be specific to the cell lines grown in our la-
boratory, and not a sequencing artifact. Moreover, we
found an excellent correlation with previously reported
variants and their frequencies for the well-characterized
reference DNA sample NA12878 from the HapMap
project [19]. The fact that all-21 variants found in the
SK-MEL-28 and HCT116 DNA samples by the CHP2
assay were confirmed by WES by the GBG from NCI,
or by ASPCR as presented here, allows us to confi-
dently report somatic variants detected in clinical spec-
imens, when all the QC criteria presented in this study
are met in the clinical run. This is in line with a re-
cently published study that concludes that confirmatory
analysis by Sanger sequencing of variants detected by
NGS testing that meets appropriate quality thresholds
is “unnecessarily redundant” [23].
Furthermore, when sequencing previously tested 55
clinical specimens, we found that the CHP2 assay per-
forms with 96.7 % sensitivity and 100.0 % specificity for
the KRAS, BRAF and EGFR genes, when compared to
single gene assays results, using as little as 1–10 ng of
FFPE DNA as template. In addition, we have identified
common variants that were called in the majority of the
samples, and we were able to ascertain that they corres-
pond to either sequencing artifacts or to SNPs with a
high global MAF. Thus, we were able to flag these com-
mon variant in our analysis pipeline, to not include
them in the final report.
It has been recommended that, in order to assure the
quality of this, or any NGS-based assay in routine clin-
ical laboratory practice, efforts should be made to estab-
lish a suitable and robust reference or control material,
and the sequence of such control material could be used
to monitor quality as the technology and/or the analysis
Table 7 Performance characteristics of the QC material
Gene
Symbol
hg19
Coordinates
Variant
Type
Variant Mean
Frequency
(%)
Standard
Deviation
%CV
BRAF 140453136 SNV A 18.5 1.5 7.9 %
EGFR 55242487 SNV T 17.1 1.4 7.9 %
EGFR 55249071 SNV T 28.6 1.7 6.1 %
EGFR 55259515 SNV G 23.4 1.5 6.5 %
KRAS 25398281 SNV A 9.6 0.7 7.0 %
KRAS 25398285 SNV T 37.9 1.1 2.8 %
PIK3CA 178952085 SNV G 9.1 1.0 11.1 %
CTNNB1 41266134 DEL CTT 11.5 2.0 17.8 %
Fig. 6 Continuous monitoring of the QC material using Levey-Jennings plots. The lowest frequency of a SNV (a) and of a small DEL (b) from the
8 variants detected in the QC material listed in Table 7 were monitored on each run over a period of 6 months using Levey-Jennings plots. The
plots show the expected mean value, previously assessed by 10 independent runs, as well as expected limits: two standard deviations (SD)
(hatched lines), and three SD (solid lines). All variants frequencies are within three standard deviations of the mean expected value
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pipeline evolve. Such a control material should be well
characterized and have similar variants as those targeted
by the assay, and should include SNVs and Indels. These
variants may be pathogenic or not, and should be located
in genomic regions targeted by the assay [24].
Therefore, we developed and tested a quality control
(QC) material by mixing, fixing and embedding the four
cell lines used in the assay validation process. The per-
formance characteristics of this control were assessed
during 10 independent consecutive runs and mean and
ranges were established to monitor each clinical run
thereafter. The fact that the QC material was created on
a patient-like matrix (i.e., FFPE cell block) makes it an
excellent quality control material to monitor every step
of the assay, from DNA extraction to data analysis
pipeline and variant calling. Also, since a single 10-μm
section is used in each batch of samples for a run, the
costs of running this QC material are dramatically lower
than those of running some commercially available ma-
terials. Moreover, the robust performance characteristics
of such QC material ensures the generation of high
quality sequence data from NGS testing of FFPE speci-
mens, even close to the limit of detection of the assay. It
is worth noting that, even though we have shown that
we are able to consistently call variants at low frequen-
cies, near 9 %, in the QC material presented here, this
alone does not ensure that variants at lower frequencies
(i.e. <9 %) will be confidently called by the assay in
every run. A thorough analytical validation, specifically
well-designed experiments to assess the LoD of the
assay, is required to ensure that low frequency variants
are reliably called by targeted NGS assays for somatic
testing of FFPE specimens.
Conclusions
In summary, during the validation process of the CHP2
assay, we have been able to customize the analysis pipe-
line, including the variant calling process, resulting in a
highly sensitive, precise and accurate clinical assay. More-
over, we successfully developed a robust QC material that
ensures consistent patient results in every clinical run.
Even more importantly, this QC material, with a relative
low manufacturing cost, has been instrumental to assess
the performance of the CHP2 assay after each instrument
preventive maintenance service, as well as minor software
upgrades, which are prone to occur frequently in this rap-
idly evolving field.
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